BGE-102
Asset
Orally available, brain-penetrant inhibitor of NLRP3 that reduces inflammatory biomarkers.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- NLRP3
- 4
- Indications
- 0
- Trials
- 1
- Developer
Indications
4Cardiovascular risk
Phase 2, ir.bioagelabs.com, 10 Oct 2026
Diabetic macular edema
Phase 2, ir.bioagelabs.com, 10 Oct 2026
Diabetic macular oedema
Phase 2, bioagelabs.com, 7 Oct 2026
1 more
In the full profile
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets4
- Competitors12
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.